Skip to Main Content

It’s been a good month for companies developing the experimental immunotherapies known as CAR-T, as several released data showing strong results in patients with blood cancers.  Now, though, they face a new challenge: Proving they can actually manufacture the highly personalized treatments quickly and efficiently — and get them to cancer patients across the country. 

And hidden in some of the positive data are hints that such turnarounds will be tough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!